Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

Th1142 details
Primary information
ID1636
ThPP IDTh1142
Therapeutic Peptide/Protein NameObinutuzumab
SequenceN.A. view full sequnce in fasta
Functional ClassificationIIb
Molecular Weight146100
Chemical FormulaC6512H10060N1712O2020S44
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half Life28.4 days
DescriptionHumanized monoclonal antibody used along with chlorambucil for the treatment of chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. It carries a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
Indication/DiseaseObinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
PharmacodynamicsObinutuzumab is more potent than rituximab in depleting B-cells, antitumor activity, and tumor regression.
Mechanism of ActionIn contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.
ToxicityThe most serious toxicities observed with obinutuzumab are Hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML). HBV reactivation can occur with all anti-CD20 antibodies and can result in hepatic failure, fulminant hepatitis, and death. PML occurs as a result of JC virus infection and can be fatal as well. Other common but less serious adverse reactions include infusion reactions (pre-treat with glucocorticoids, acetaminophen, and anti-histamine to prevent this), neutropenia, thrombocytopenia, and Tumor Lysis Syndrome (TLS) (pre-treat patients, especially with a high lymphocyte count and/or a high tumor burden, with anti-hyperuricemics and hydration). It is also recommended to NOT administer live virus vaccinations prior to or during obinutuzumab treatment.
MetabolismObinutuzumab is not metabolized by the liver.
AbsorptionObinutuzumab is administered intravenously, so its absorption is 100%.
Volume of DistributionObinutuzumab has a volume of distribution of about 3.8 L.
ClearanceThe clearance of obinutuzumab is 0.09L/day.
CategoriesAntineoplastic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetB-lymphocyte antigen CD20
Information of corresponding available drug in the market
Brand NameGazyva
CompanyGenentech
Brand DiscriptionGAZYVA (obinutuzumab) is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells. The molecular mass of the antibody is approximately 150 kDa.
Prescribed forchronic lymphocytic leukemia (CLL)
Chemical NameN.A.
FormulationGAZYVA is supplied at a concentration of 25 mg/mL in 1000 mg single use vials. The product is formulated in 20 mM L-histidine/L-histidine hydrochloride, 240 mM trehalose, 0.02% poloxamer 188. The pH is 6.0.
Physcial AppearanceGAZYVA is produced by mammalian cell (CHO) suspension culture. GAZYVA is a sterile, clear, colorless to slightly brown, preservative free liquid concentrate for intravenousadministration.
Route of AdministrationIntravenous infusion
Recommended DosageEach dose of GAZYVA is 1000 mg, administered intravenously, with the exception of the first infusions in cycle 1, which are administered on day 1 (100 mg) and day 2 (900 mg).
ContraindicationN.A.
Side EffectsHepatitis B reactivation, Progressive multifocal leukoencephalopathy, Infusion reactions, Tumor lysis syndrome, Infections, Neutropenia, Thrombocytopenia.
Useful Linkhttp://www.rxlist.com/gazyva-drug.htm http://www.gazyva.com/ http://www.roche.com/media/store/releases/med-cor-2013-11-01.htm
PubMed ID25634683, 25586272, 25538980, 25355689, 25353187
3-D StructureN.A.